# Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT05597306** · PHASE1 · RECRUITING · sponsor: **Terrence J Bradley, MD** · enrollment: 18 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Acute Myeloid Leukemia, in Relapse

## Interventions

- **DRUG:** Bomedemstat
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05597306
- **Lead sponsor:** Terrence J Bradley, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-19
- **Primary completion:** 2026-11-19
- **Final completion:** 2026-11-19
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05597306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05597306, "Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05597306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*